Differential Labeling by Monoclonal Antibodies Adnab-9 and Anti-?-Defensin 5 Based on the Distribution and Adenomatous Tissue Content of Colonic Polyps

Abstract

We sought a correlation between site and morphology of colonic polyps by labeling with neoplastic and general Paneth cell markers, monoclonal antibodies Adnab-9 and anti-alpha-defensin 5, respectively. Proportions labeled by Adnab-9 and anti-alpha-defensin 5 were, respectively, 42 and 85% for adenomas, 39 and 63% for early tubular adenomas, 41 and 44% for serrated, 34 and 20% for mixed, and 11 versus 2.7% for hyperplastic polyps. Compared with hyperplastic polyps, the proportion of other polyps labeled by Adnab-9 or anti-alpha-defensin 5 was higher but this difference was more significant for distal (P = 0.008 for Adnab-9 and P = 0.0001 for anti-alpha-defensin 5) than proximal (P = 0.645 and P = 0.154, respectively) polyps. While increased labeling of all proximal polyps compared to distal ones mirrored the colonic distribution of Paneth cells, distal adenomas tended to have a higher proportion labeled by Adnab-9, suggesting that Adnab-9 labels Paneth cells associated with increased neoplastic potential.

Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/β-catenin/Tcf pathway

“…Ullah et al [27] were the first to examine HD-5 expression in colorectal polyps. They reported that 85% of CAs, 44% of serrated adenomas, 20% of MPs, and 2.7% of HPs showed HD-5 expression.…”

An Anti-adenoma Antibody, Adnab-9, May Reflect the Risk for Neoplastic Progression in Familial Hamartomatous Polyposis Syndromes

“…Adnab-9 monoclonal antibody (mouse ascites) was used at a 1:1,000 dilution and the substrate was 3-amino-9-ethyl-carbazole (AEC). AD5 (kindly supplied by Dr. T. Ganz, UCLA) was used at 1:5,000 as described previously [17], to label hyperplastic and PJS polyp sections. Due to limitations of the tissue supply, FJP sections were not labeled for a-defensin 5.…”